#United States #Robbins Geller #San Diego #Inc. #class action lawsuit #RxSight

Important Announcement for RxSight Investors

Robbins Geller Rudman & Dowd LLP has formally announced the initiation of a class action lawsuit against RxSight, Inc., under the case name Makaveev v. RxSight, Inc., currently pending in California's Central District. This lawsuit aims to represent all investors who purchased or acquired shares of RxSight, Inc. (NASDAQ: RXST) during the class period and suffered substantial financial losses.

Background of the Lawsuit

The lawsuit centers around allegations that RxSight, along with its top executives, violated the Securities Exchange Act of 1934. Specifically, the class action claims that the defendants made misleading statements and failed to disclose crucial information regarding the company's operational challenges, leading to an overstated demand for its products.

Allegations and Financial Impacts

The complaint indicates that throughout the class period, RxSight faced significant hurdles related to the adoption of its innovative light adjustable intraocular lenses (LALs), which are essential for cataract surgery. Reports reveal that RxSight experienced a severe decline in sales and overall product utilization. On July 8, 2025, the company disclosed preliminary financial results, highlighting a substantial downturn in Light Delivery Device (LDD) sales and lowering its financial forecasts by approximately $42.5 million at the midpoint.

The CEO, Ronald Kurtz, attributed these setbacks to persistent adoption challenges that have plagued the company. Following this disheartening news, RxSight's stock price plunged nearly 38%, further amplifying the losses sustained by investors.

Opportunity for Investors

Investors who believe they have incurred significant losses in purchasing or acquiring RxSight securities during this period now have the chance to step forward and potentially act as lead plaintiffs in the lawsuit. Under the Private Securities Litigation Reform Act of 1995, any affected investor can apply to lead the action. This position is typically sought by the investor with the largest financial stake in the outcomes of the lawsuit, who will advocate on behalf of the entire class.

It is important to note that serving as the lead plaintiff does not affect an investor's right to any future recovery. Investors can choose the law firm they prefer for representation, and Robbins Geller, known for its track record in securing substantial monetary relief for investors in various securities-related cases, is dedicated to ensuring comprehensive support for all class members.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP stands as one of the preeminent legal firms worldwide, specializing in securities litigation and representing investors harmed by market misconduct. The firm has made headlines for its ability to recover significant sums for investors, including over $2.5 billion in 2024 alone, a testament to its unparalleled expertise in class action lawsuits.

For further information or to express your interest in joining the class action lawsuit, potential lead plaintiffs can reach out to Robbins Geller attorneys J.C. Sanchez or Jennifer N. Caringal via phone at 800-449-4900 or through email at [email protected].

Deadlines for Action

The deadline to file lead plaintiff motions for this class action lawsuit is September 22, 2025. Investors should act promptly to safeguard their interests and ensure their voices are represented in this legal matter.

As developments unfold in this significant class action, affected investors are encouraged to remain informed and engaged to protect their rights and financial interests.